MA63787B1 - Nouvel agent de contraste pour une utilisation dans l'imagerie par résonance magnétique - Google Patents

Nouvel agent de contraste pour une utilisation dans l'imagerie par résonance magnétique

Info

Publication number
MA63787B1
MA63787B1 MA63787A MA63787A MA63787B1 MA 63787 B1 MA63787 B1 MA 63787B1 MA 63787 A MA63787 A MA 63787A MA 63787 A MA63787 A MA 63787A MA 63787 B1 MA63787 B1 MA 63787B1
Authority
MA
Morocco
Prior art keywords
magnetic resonance
contrast agent
resonance imaging
new contrast
compounds
Prior art date
Application number
MA63787A
Other languages
English (en)
Inventor
Sven WITTROCK
Gregor Jost
Hubertus Pietsch
Markus Berger
Jessica LOHRKE
Thomas Frenzel
Thomas Brumby
Simon Anthony Herbert
Olaf Panknin
Claudia GREEN
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of MA63787B1 publication Critical patent/MA63787B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne une nouvelle classe de composés de formule générale (I), les complexes chélates Gd3+ de ceux-ci, des procédés de préparation desdits composés, et l'utilisation desdits composés en tant qu'agents de contraste IRM. Formule (I)
MA63787A 2021-03-15 2022-03-14 Nouvel agent de contraste pour une utilisation dans l'imagerie par résonance magnétique MA63787B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21162650.2A EP4059925A1 (fr) 2021-03-15 2021-03-15 Nouvel agent de contraste pour une utilisation dans l'imagerie par résonance magnétique
PCT/EP2022/056541 WO2022194777A1 (fr) 2021-03-15 2022-03-14 Nouvel agent de contraste destiné à être utilisé dans l'imagerie par résonance magnétique
EP22714807.9A EP4308551B1 (fr) 2021-03-15 2022-03-14 Nouvel agent de contraste pour une utilisation dans l'imagerie par résonance magnétique

Publications (1)

Publication Number Publication Date
MA63787B1 true MA63787B1 (fr) 2025-07-31

Family

ID=74874752

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63787A MA63787B1 (fr) 2021-03-15 2022-03-14 Nouvel agent de contraste pour une utilisation dans l'imagerie par résonance magnétique

Country Status (21)

Country Link
US (1) US20240182431A1 (fr)
EP (2) EP4059925A1 (fr)
JP (1) JP2024512459A (fr)
KR (1) KR20230157412A (fr)
CN (1) CN116981658A (fr)
AR (1) AR126325A1 (fr)
AU (1) AU2022236333A1 (fr)
CA (1) CA3213386A1 (fr)
CL (1) CL2023002723A1 (fr)
CO (1) CO2023012137A2 (fr)
CR (1) CR20230433A (fr)
DO (1) DOP2023000185A (fr)
EC (1) ECSP23070062A (fr)
ES (1) ES3034297T3 (fr)
GE (2) GEP20257722B (fr)
IL (1) IL305294A (fr)
JO (1) JOP20230216A1 (fr)
MA (1) MA63787B1 (fr)
MX (1) MX2023010737A (fr)
PE (1) PE20240821A1 (fr)
WO (1) WO2022194777A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210069A1 (fr) * 2022-01-11 2023-07-12 Bayer Aktiengesellschaft Images tomodensitométriques synthétiques à contraste amélioré
US20260087709A1 (en) 2022-08-30 2026-03-26 Bayer Aktiengesellschaft Generation of synthetic radiological images
EP4581641A1 (fr) 2022-08-30 2025-07-09 Bayer Aktiengesellschaft Génération d'images radiologiques synthétiques
EP4581640B1 (fr) 2022-08-30 2026-04-22 Bayer Aktiengesellschaft Production d'enregistrements radiologiques synthétiques
JP2025531766A (ja) 2022-09-05 2025-09-25 バイエル、アクチエンゲゼルシャフト 人工造影放射線画像の生成
EP4336204A1 (fr) 2022-09-07 2024-03-13 Bayer AG Accélération d'examens irm du foie
EP4335462A1 (fr) * 2022-09-09 2024-03-13 Bayer AG Nouveaux agents de contraste pour l'imagerie diagnostique par tomodensitometrie
WO2024083466A1 (fr) 2022-10-17 2024-04-25 Bayer Aktiengesellschaft Analyse automatisée d'images radiologiques
CN116444428A (zh) * 2022-10-25 2023-07-18 无锡贝塔医药科技有限公司 一种吡啶环3-位引入c-14标记的乙醇基团的方法
EP4369285A1 (fr) 2022-11-12 2024-05-15 Bayer AG Génération d'enregistrements radiologiques artificiels renforcés par un agent de contraste
EP4369353A1 (fr) 2022-11-12 2024-05-15 Bayer Aktiengesellschaft Génération d'enregistrements radiologiques artificiels renforcés par un agent de contraste
EP4375919A1 (fr) 2022-11-25 2024-05-29 Bayer AG Génération d'enregistrements radiologiques synthétiques à contraste amélioré
EP4471710B1 (fr) 2023-05-30 2025-12-17 Bayer Aktiengesellschaft Détection d'artéfacts dans des enregistrements médicaux synthétiques
EP4475137B1 (fr) 2023-06-05 2025-12-03 Bayer Aktiengesellschaft Génération d'enregistrements radiologiques artificiels à contraste amélioré
EP4485474B1 (fr) 2023-06-05 2026-04-08 Bayer Aktiengesellschaft Génération d'enregistrements radiologiques artificiels à contraste amélioré
US20250045926A1 (en) 2023-07-25 2025-02-06 Bayer Aktiengesellschaft Detection of artifacts in synthetic images
EP4567716A1 (fr) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Génération de représentations synthétiques
EP4567715A1 (fr) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Génération de représentations synthétiques
EP4571650A1 (fr) 2023-12-12 2025-06-18 Bayer AG Génération d'images synthétiques
WO2025190827A1 (fr) 2024-03-15 2025-09-18 Bayer Aktiengesellschaft Génération d'une image médicale synthétique
WO2025190828A1 (fr) 2024-03-15 2025-09-18 Bayer Aktiengesellschaft Correction d'une image irm
EP4618009A1 (fr) 2024-03-15 2025-09-17 Bayer Aktiengesellschaft Génération d'une image médicale synthétique
EP4664393A1 (fr) 2024-06-10 2025-12-17 Bayer Aktiengesellschaft Génération d'enregistrements radiologiques synthétiques à contraste amélioré

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
DE3922005A1 (de) 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
GB9407435D0 (en) 1994-04-14 1994-06-08 Nycomed Salutar Inc Compounds
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
DE19507820A1 (de) * 1995-02-21 1996-08-22 Schering Ag Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
IT1293778B1 (it) 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
AU2001259575A1 (en) 2000-05-04 2001-11-12 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10231799B4 (de) 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005033902B3 (de) 2005-07-15 2007-04-05 Schering Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
WO2013083535A1 (fr) 2011-12-05 2013-06-13 Bracco Imaging Spa Composition comprenant de l'anhydride acétique et un complexe de gadolinium, et procédé d'utilisation dans l'analyse irm avec hyperpolarisation
CA3137963A1 (fr) * 2019-04-26 2020-10-29 Five Eleven Pharma Inc. Inhibiteurs de l'antigene membranaire specifique de la prostate (psma) en tant qu'agents diagnostiques et agents therapeutiques de type radionucleides

Also Published As

Publication number Publication date
CO2023012137A2 (es) 2023-09-29
DOP2023000185A (es) 2023-10-15
CN116981658A (zh) 2023-10-31
BR112023017197A2 (pt) 2023-09-26
PE20240821A1 (es) 2024-04-18
TW202302543A (zh) 2023-01-16
US20240182431A1 (en) 2024-06-06
ECSP23070062A (es) 2023-10-31
CR20230433A (es) 2023-10-23
KR20230157412A (ko) 2023-11-16
EP4308551A1 (fr) 2024-01-24
CA3213386A1 (fr) 2022-09-22
MX2023010737A (es) 2023-09-20
EP4308551B1 (fr) 2025-04-09
WO2022194777A1 (fr) 2022-09-22
GEP20257722B (en) 2025-01-27
JP2024512459A (ja) 2024-03-19
JOP20230216A1 (ar) 2023-09-14
CL2023002723A1 (es) 2024-01-26
IL305294A (en) 2023-10-01
GEAP202416374A (en) 2024-01-10
EP4059925A1 (fr) 2022-09-21
ES3034297T3 (en) 2025-08-14
AU2022236333A1 (en) 2023-08-31
EP4308551C0 (fr) 2025-04-09
AR126325A1 (es) 2023-10-04

Similar Documents

Publication Publication Date Title
MA63787B1 (fr) Nouvel agent de contraste pour une utilisation dans l'imagerie par résonance magnétique
MX374249B (es) Nuevos compuestos de quelato de gadolinio para usar en imágenes de resonancia magnética.
MX339144B (es) Nuevas drogas para inhibir la agregacion de proteinas involucradas en enfermedades relacionadas con la agregacion de proteinas y/o enfermedades neurodegenerativas.
BRPI0617151B8 (pt) composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico
GEP20237496B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
ATE430146T1 (de) Kontrastmittel mit hoher relaxivität zur verwendung in der magnetresonanzbilddarstellung (mri), enthaltend eine chelatbildende gruppe mit polyhydroxylierten substituenten
MX2010009959A (es) Compuestos y metodo para reducir el acido urico.
EP2098522A4 (fr) Nouveau composé ayant une affinité pour l'amyloïde
WO2014037498A3 (fr) Nanoparticules lipidiques solides paramagnétiques (psln) contenant des complexes amphiphiles métalliques pour imagerie par résonance magnétique (irm)
RU2008147002A (ru) Новые соединения, обладающие сродством к амилоиду
MX2025004774A (es) Proceso para la preparacion de un agente de contraste de gadolinio
RU2008112676A (ru) Противоопухолевое средство
NO20080813L (no) Komplekser inneholdende perfluoralkyl, fremgangsmate for fremstilling og anvendelse derav
JP2015509966A5 (fr)
NO20081655L (no) Fremgangsmate for fremstilling av kontrastmidler
TW200740777A (en) Perfluoroalkyl-containing complexes, process for their production as well as their use
BR112022003242A2 (pt) Composto, composição, e, métodos de formação de imagens, de síntese enantiosseletiva e de produção
MY201491A (en) Nanoparticle, contrast agent for magnetic resonance imaging containing same, and ligand compound
PH12021551522A1 (en) Nanoparticle, contrast agent for magnetic resonance imaging comprising same and zwitterionic ligand compound
TW200606172A (en) Galactopyrannosyltriaminetetracarboxylate as ligands for bio-activated paramagnetic metal complexes
NZ787150A (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
TR201922587A2 (tr) Pi̇ri̇doksal hi̇droklorür esasli ni̇kel ve rutenyum ti̇yosemi̇karbazon kompleksleri̇ ve bunlarin anti̇oksi̇dan ajan olarak kullanimlari
RU2008142157A (ru) Высокорелаксивные комплексы гадолиния
IN2013DE03806A (fr)